PE20020411A1 - Compuestos derivados de la triptamina y sus analogos que interactuan con el sistema melatoninergico - Google Patents
Compuestos derivados de la triptamina y sus analogos que interactuan con el sistema melatoninergicoInfo
- Publication number
- PE20020411A1 PE20020411A1 PE2001000960A PE2001000960A PE20020411A1 PE 20020411 A1 PE20020411 A1 PE 20020411A1 PE 2001000960 A PE2001000960 A PE 2001000960A PE 2001000960 A PE2001000960 A PE 2001000960A PE 20020411 A1 PE20020411 A1 PE 20020411A1
- Authority
- PE
- Peru
- Prior art keywords
- triptamine
- alkyl
- interact
- dinitro
- analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A DERIVADOS DE LA TRIPTAMINA DONDE R1, R2 Y R3 SON H, HALOGENO, ALQUILO C1-C4, ALCOXI C1-C4, NR'R'', N(R')C(:O)R0, NITRO, ARILO, ENTRE OTROS; R0 ES ALQUILO C1-C4, ARILO; R' Y R'' SON H, ALQUILO C1-C4; m ES 0-4; t ES 0-3; X ES NH, N-(ALQUILO C1-C4), O, S CON LA CONDICION DE QUE X NO ES NH CUANDO SIMULTANEAMENTE (R1)m ES 5-METOXI, R2 ES H, I Y t ES 0. SON COMPUESTOS PREFERIDOS N-(2,4-DINITROFENIL)TRIPTAMINA, N-(2,4-DINITROFENIL)-5-METILTRIPTAMINA, 2,4-DINITRO-5-TRIPTAMINOACETANILIDA , 2,4-DINITRO-5-(5'-METILTRIPTIL)AMINOACETANILIDA, N-(2,4-DINITRO-5-AMINOFENIL)TRIPTAMINA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS INTERACTUAN CON EL SISTEMA MELATONINERGICO Y SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL, TRASTORNOS DEL SUENO, EPILEPSIA, ASIEDAD, ENFERMEDADES NEURODEGENERATIVAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL138825A IL138825A (en) | 2000-10-03 | 2000-10-03 | Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020411A1 true PE20020411A1 (es) | 2002-05-16 |
Family
ID=11074694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000960A PE20020411A1 (es) | 2000-10-03 | 2001-09-26 | Compuestos derivados de la triptamina y sus analogos que interactuan con el sistema melatoninergico |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US6780884B2 (es) |
| EP (1) | EP1331935B1 (es) |
| JP (1) | JP2004533986A (es) |
| KR (1) | KR100855385B1 (es) |
| CN (1) | CN100518735C (es) |
| AR (1) | AR035587A1 (es) |
| AT (1) | ATE409474T1 (es) |
| AU (1) | AU9416201A (es) |
| BG (1) | BG107759A (es) |
| BR (1) | BR0114464A (es) |
| CA (1) | CA2423628C (es) |
| CL (1) | CL2001002303A1 (es) |
| CR (1) | CR6968A (es) |
| CY (1) | CY1110417T1 (es) |
| CZ (1) | CZ301098B6 (es) |
| DE (1) | DE60136003D1 (es) |
| DK (1) | DK1331935T3 (es) |
| EA (1) | EA005918B1 (es) |
| EE (1) | EE05192B1 (es) |
| ES (1) | ES2315307T3 (es) |
| GT (1) | GT200100197A (es) |
| HK (1) | HK1074163A1 (es) |
| HN (1) | HN2001000218A (es) |
| HU (1) | HU227163B1 (es) |
| IL (1) | IL138825A (es) |
| IS (1) | IS2607B (es) |
| MX (1) | MXPA03002612A (es) |
| NO (1) | NO20031396L (es) |
| NZ (1) | NZ525587A (es) |
| PA (1) | PA8529801A1 (es) |
| PE (1) | PE20020411A1 (es) |
| PL (1) | PL365679A1 (es) |
| PT (1) | PT1331935E (es) |
| SI (1) | SI1331935T1 (es) |
| SK (1) | SK4042003A3 (es) |
| TW (1) | TWI270544B (es) |
| UA (1) | UA75091C2 (es) |
| UY (1) | UY26946A1 (es) |
| WO (1) | WO2002028347A2 (es) |
| ZA (1) | ZA200303113B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005060711A2 (en) * | 2003-12-19 | 2005-07-07 | Elixir Pharmaceuticals, Inc. | Methods of treating a disorder |
| CA2556753C (en) * | 2004-02-20 | 2014-11-25 | Lifescape Biosciences Incorporated | Compositions and methods for sleep regulation |
| CN101233121A (zh) * | 2005-06-10 | 2008-07-30 | 彼帕科学公司 | Parp调节剂和癌症的治疗 |
| US7622495B2 (en) | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| AU2008271911B2 (en) | 2007-06-29 | 2014-08-07 | Phovitreal Pty Ltd | Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration |
| CA2723816C (en) * | 2008-05-13 | 2017-06-20 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
| US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
| KR20220083846A (ko) | 2011-05-31 | 2022-06-20 | 클라렌슈 피티와이 리미티드 | 광선 요법 장치 |
| WO2013063492A1 (en) * | 2011-10-28 | 2013-05-02 | Board Of Regents, The University Of Texas System | Novel compositions and methods for treating cancer |
| CN102816103B (zh) * | 2012-08-20 | 2014-05-07 | 冉瑞琼 | 硫化天冬氨酸修饰的退黑素衍生物及其应用 |
| SG11201807079UA (en) * | 2016-03-14 | 2018-09-27 | Somalogic Inc | Compounds and methods for the synthesis of 5-(n-protected-tryptaminocarboxyamide)-2'-deoxyuridine phosphoramidate for incorporation into a nucleic sequence |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL79264A0 (en) * | 1986-06-27 | 1986-09-30 | Univ Ramot | Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors |
| US6310085B1 (en) * | 1997-10-03 | 2001-10-30 | Clarencew Pty Ltd. | Method for the treatment of neurological or neuropsychiatric disorders |
| AUPO274596A0 (en) * | 1996-10-04 | 1996-10-31 | Armstrong, Stuart Maxwell | Method for the treatment of neurological or neuropsychiatric disorders |
-
2000
- 2000-10-03 IL IL138825A patent/IL138825A/en not_active IP Right Cessation
-
2001
- 2001-09-14 TW TW090122940A patent/TWI270544B/zh not_active IP Right Cessation
- 2001-09-25 CA CA2423628A patent/CA2423628C/en not_active Expired - Fee Related
- 2001-09-25 KR KR1020037004661A patent/KR100855385B1/ko not_active IP Right Cessation
- 2001-09-25 CL CL2001002303A patent/CL2001002303A1/es unknown
- 2001-09-25 UY UY26946A patent/UY26946A1/es not_active Application Discontinuation
- 2001-09-25 CN CNB018168043A patent/CN100518735C/zh not_active Expired - Fee Related
- 2001-09-25 US US10/381,976 patent/US6780884B2/en not_active Expired - Fee Related
- 2001-09-25 AR ARP010104520A patent/AR035587A1/es unknown
- 2001-09-25 CZ CZ20030940A patent/CZ301098B6/cs not_active IP Right Cessation
- 2001-09-25 UA UA2003043421A patent/UA75091C2/uk unknown
- 2001-09-25 MX MXPA03002612A patent/MXPA03002612A/es active IP Right Grant
- 2001-09-25 BR BR0114464-2A patent/BR0114464A/pt not_active Application Discontinuation
- 2001-09-25 ES ES01974651T patent/ES2315307T3/es not_active Expired - Lifetime
- 2001-09-25 EP EP01974651A patent/EP1331935B1/en not_active Expired - Lifetime
- 2001-09-25 DE DE60136003T patent/DE60136003D1/de not_active Expired - Lifetime
- 2001-09-25 EA EA200300436A patent/EA005918B1/ru not_active IP Right Cessation
- 2001-09-25 JP JP2002531973A patent/JP2004533986A/ja active Pending
- 2001-09-25 SK SK404-2003A patent/SK4042003A3/sk unknown
- 2001-09-25 EE EEP200300135A patent/EE05192B1/xx not_active IP Right Cessation
- 2001-09-25 AT AT01974651T patent/ATE409474T1/de active
- 2001-09-25 NZ NZ525587A patent/NZ525587A/en unknown
- 2001-09-25 WO PCT/IL2001/000898 patent/WO2002028347A2/en active IP Right Grant
- 2001-09-25 DK DK01974651T patent/DK1331935T3/da active
- 2001-09-25 PL PL01365679A patent/PL365679A1/xx not_active Application Discontinuation
- 2001-09-25 AU AU9416201A patent/AU9416201A/xx not_active Withdrawn
- 2001-09-25 SI SI200130889T patent/SI1331935T1/sl unknown
- 2001-09-25 HU HU0302616A patent/HU227163B1/hu not_active IP Right Cessation
- 2001-09-25 PT PT01974651T patent/PT1331935E/pt unknown
- 2001-09-26 PE PE2001000960A patent/PE20020411A1/es not_active Application Discontinuation
- 2001-09-27 GT GT200100197A patent/GT200100197A/es unknown
- 2001-10-01 PA PA20018529801A patent/PA8529801A1/es unknown
- 2001-10-02 HN HN2001000218A patent/HN2001000218A/es unknown
-
2003
- 2003-03-21 IS IS6752A patent/IS2607B/is unknown
- 2003-03-27 NO NO20031396A patent/NO20031396L/no not_active Application Discontinuation
- 2003-04-23 ZA ZA200303113A patent/ZA200303113B/xx unknown
- 2003-04-24 BG BG107759A patent/BG107759A/bg unknown
- 2003-05-02 CR CR6968A patent/CR6968A/es unknown
-
2004
- 2004-08-20 US US10/921,823 patent/US20050020664A1/en not_active Abandoned
-
2005
- 2005-06-24 HK HK05105286.7A patent/HK1074163A1/xx not_active IP Right Cessation
-
2008
- 2008-12-22 CY CY20081101480T patent/CY1110417T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR002289A1 (es) | Derivados de acetamida, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y las aplicaciones de dichos compuestos comoansioliticos y en el tratamiento de enfermedades inmuno-inflamatorias. | |
| ES2119124T3 (es) | Bencimidazoles utiles para el tratamiento de trastornos del sistema nervioso. | |
| ECSP055536A (es) | Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6 | |
| ECSP055535A (es) | Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6 | |
| UY28150A1 (es) | Agentes terapeuticos | |
| PE20010205A1 (es) | Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato | |
| PA8442201A1 (es) | Derivados de 6-fenilpiridil-2-amina | |
| AR007118A1 (es) | 4(3h)-quinazolinonas 2,3 disustituidas y composiciones farmaceuticas que las contienen | |
| PE20020411A1 (es) | Compuestos derivados de la triptamina y sus analogos que interactuan con el sistema melatoninergico | |
| CO4810373A1 (es) | Compuestos azapoliciclicos condensados con arilo | |
| BRPI0415657A (pt) | derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c | |
| SE9702564D0 (sv) | New compounds | |
| BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
| ECSP045473A (es) | Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6 | |
| MX9202190A (es) | 2-carboxiindoles substituidos que tienen actividad farmaceutica. | |
| ES2150671T3 (es) | Compuesto de bencimidazol y su utilizacion como moduladores del complejo de receptores gaba-a. | |
| FI965021A (fi) | Bentsimidatsolijohdannaisia, joilla on dopaminergistä vaikutusta keskushermostossa | |
| DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| PA8458301A1 (es) | 2-aminopiridinas con sustituyentes alcoxi ramificados | |
| AR016551A1 (es) | Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos | |
| ES2051954T3 (es) | 2-aminotiazoles substituidos. | |
| DK0431579T3 (da) | Substituerede cyclohexener som midler med virkning på centralnervesystemet | |
| KR950700257A (ko) | 콜레시스토키닌 길항제로서 유용한 3-페닐우레이도-아제핀-2-온 및 벤즈아제핀-2-온(3-phenylureido-azepin-2-ones and-benzazepin-2-ones useful as cholecystokinin antagonists) | |
| PE20011260A1 (es) | Derivados de sulfonamida | |
| HUP0302255A2 (hu) | Szulfonamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |